+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ovarian Cancer Drugs Market Research Reports

From
From
From
From
From
From
Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2022 - Product Thumbnail Image

Advanced Recurrent Ovarian Cancer- Pipeline Insight, 2022

  • Clinical Trials
  • July 2022
  • 60 Pages
From
From
From
From
Global Ovarian Cancer Drugs Market 2022-2028 - Product Thumbnail Image

Global Ovarian Cancer Drugs Market 2022-2028

  • Report
  • April 2022
  • 115 Pages
From
Global Gemcitabine Hydrochloride Market 2022-2026 - Product Thumbnail Image

Global Gemcitabine Hydrochloride Market 2022-2026

  • Report
  • March 2022
  • 120 Pages
From
From
Fallopian tube cancer - Pipeline Insight, 2022 - Product Thumbnail Image

Fallopian tube cancer - Pipeline Insight, 2022

  • Clinical Trials
  • February 2022
  • 120 Pages
From
Global Etoposide Market 2021-2027 - Product Thumbnail Image

Global Etoposide Market 2021-2027

  • Report
  • February 2022
  • 103 Pages
From
From
Loading Indicator

Far less common than breast cancer, but with a higher mortality rate, sufferers of ovarian cancer are experiencing significant unmet needs. There are therefore considerable market opportunities for drug designers and manufacturers in this life-saving sector of the pharmaceutical industry. In this section a host of cutting edge reports provide valuable insight into key markets such as China and the US, the latest drug development activities and the market trends (including sales, pricing and forecasts) for specific drugs like Doxil, Caelyx, Yondelis and Paclitaxel. You can also purchase reports that feature the latest strategies of major and niche industry players such as Alza Corporation, Amgen, Bristol-Myers Squibb, Cell Therapeutics, Genentech, GlaxoSmithKline, Immunogen, Ivax, OSI Pharmaceuticals and Raven Biotechnologies.
Show Less
Read more